查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
2014924

肝纤维化治疗市场：按药物类别、作用机制、给药途径和分销管道分類的全球市场预测，2026-2032年

Liver Fibrosis Drugs Market by Drug Class, Mechanism Of Action, Route Of Administration, Distribution Channel - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 196 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2025 年，肝纤维化治疗市场价值将达到 171.2 亿美元，到 2026 年将成长至 188.3 亿美元，到 2032 年将达到 337 亿美元，年复合成长率为 10.15%。

主要市场统计数据
基准年 2025 171.2亿美元
预计年份：2026年 188.3亿美元
预测年份 2032 337亿美元
复合年增长率 (%) 10.15%

对影响肝纤维化治疗发展和相关人员优先事项的不断变化的治疗、监管和商业性环境进行权威说明。

肝纤维化处于未满足的医疗需求、科学创新和商业性机会三者交会的关键位置。过去十年，我们对创伤治疗、细胞外基质重塑和免疫代谢的理解不断深入，并将肝纤维化的进展从不可避免的临床终点转变为可治疗的标靶。这种模式转移正在加速开发更多样化的治疗方法，促进肝病学和免疫学专家之间的跨学科合作，并提升连接机制与临床结果的转化生物标记的重要性。

科学突破、治疗方法扩展和创新试验设计如何从根本上改变肝纤维化的治疗策略和相关人员的行为。

肝纤维化领域正经历一场变革，主要得益于科学突破、治疗方法的多样化以及临床试验框架的变革。对纤维化诱导讯号网络的分子层级解析使得标靶治疗更加精准，而生物製药、细胞和基因疗法以及小分子化合物的设计进步则进一步拓展了治疗手段。随着治疗方法的多样化，研发人员越来越重视将作用机制与疾病表型相匹配，优先研发能够调节纤维化核心驱动因素的药物，而非仅仅抑制相关的发炎反应。

本研究评估了美国关税政策的最新变化对肝纤维化治疗药物研发中的供应链韧性、筹资策略和商业规划的影响。

美国近期关税政策的变化为支撑药品研发和商业化的全球供应链带来了新的复杂性。关税调整影响活性药物成分的采购以及生物製药生产所需特殊原料的采购。依赖跨境采购零件的製造商被迫重新评估其供应商合约、库存策略和成本结构，以维持供应的连续性并保护利润率。

将药物类别、作用机制、给药途径和分销管道联繫起来的多方面细分洞察，有助于制定开发和商业化策略。

了解细分市场对于将研发和商业策略与治疗机会相匹配至关重要。若依治疗方法类别将治疗方法分类，则可分为生物製药、细胞疗法、基因疗法及小分子抑制剂。在生物製药类别中，单株抗体和重组蛋白作为能够实现标靶特异性和免疫反应调节的平台正日益受到关注。另一方面，小分子抑制剂既包括天然来源的骨架，也包括可口服给药或作用于细胞内标靶的合成优化化合物。

影响多个全球医疗保健生态系统中监管参与、证据产生和商业性实施的区域发展和准入趋势。

区域趋势对研发重点、监理互动和商业性化途径有显着影响。在美洲，监管机构和保险支付方强调真实世界疗效和基于价值的合同，这鼓励申办方制定能够证明可持续临床疗效和降低医疗成本的证据生成策略。该地区的临床网络和学术机构也积极参与患者招募和生物标记检验活动，从而影响早期试验设计和转化研究合作。

在肝纤维化治疗领域，企业策略、伙伴关係和平台能力如何融合，进而推动差异化的产品线和协作方式？

肝纤维化领域的企业策略以平台主导创新、标靶产品开发和策略合作的整合为特征。生技公司正利用高度弹性的转化研发管线和精准的病患辨识策略，推动差异化的作用机制和First-in-Class药物的研发。大型製药企业也日益寻求与创新者建立合作关係，以加速后期研发并拓展其治疗产品组合，从而提供规模优势、监管谈判经验和商业化基础设施。

采取切实可行的策略性倡议，透过协调转化生物标记、供应链韧性、与区域监管机构的合作以及伙伴关係模式，加速治疗药物的成功上市。

产业领导者应优先考虑一系列切实可行的倡议，使科学预期与实际商业性现实相契合。首先，他们应儘早整合转化生物标记策略，以降低临床计画风险，并明确作用机制与临床终点之间的关联。这种契合将有助于与监管机构进行对话，并增强对支付方的价值提案。其次，他们应透过多元化关键原材料供应商、评估区域生产方案以及製定紧急时应对计画来增强价值链韧性，从而维持临床和商业性的连续性。

采用严谨的混合方法研究途径，结合专家访谈、系统性的二手文献综述和营运分析，以检验治疗和商业性的发现。

本报告的研究融合了多种调查方法，以确保其观点稳健可靠且基于实证。主要研究包括对肝病临床专家、监管顾问、行业高管和供应链专家进行结构化访谈，以了解当前的临床实践模式、监管预期和营运限制。透过整合这些定性见解，我们对治疗差异化进行了背景分析，并确定了影响研发和商业化策略的关键决策点。

一份权威的综合分析报告，重点阐述了在科学、临床开发、运营和商业性实施方面可采取的优先事项，以实现肝纤维化治疗的持续疗效。

总而言之，肝纤维化的治疗格局正从概念设想转向实际应用。生物目标知识和治疗方法工程领域的科学进步正在拓宽可行的干预措施范围，而诊断和临床试验设计的创新则使得概念验证（PoC）更有效率。同时，研发、生产和商业化团队之间需要进行整合规划，以应对从供应链变化到关税相关采购考量等各种营运压力。

目录

第一章：序言

第二章：调查方法

  • 调查设计
  • 研究框架
  • 市场规模预测
  • 数据三角测量
  • 调查结果
  • 调查的前提
  • 研究限制

第三章执行摘要

  • 首席主管观点
  • 市场规模和成长趋势
  • 2025年市占率分析
  • FPNV定位矩阵，2025
  • 新的商机
  • 下一代经营模式
  • 产业蓝图

第四章 市场概览

  • 产业生态系与价值链分析
  • 波特五力分析
  • PESTEL 分析
  • 市场展望
  • 市场进入策略

第五章 市场洞察

  • 消费者洞察与终端用户观点
  • 消费者体验基准
  • 机会映射
  • 分销通路分析
  • 价格趋势分析
  • 监理合规和标准框架
  • ESG与永续性分析
  • 中断和风险情景
  • 投资报酬率和成本效益分析

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

第八章：肝纤维化治疗市场：依药物类别划分

  • 生物製药
    • 单株抗体
    • 重组蛋白
  • 细胞疗法
  • 基因治疗
  • 小分子抑制剂
    • 天然产品
    • 合成化合物

第九章：肝纤维化治疗药物市场－依作用机转划分

  • ASK1抑制剂
  • 半乳糖凝集素-3抑制剂
  • PPAR促效剂
    • PDOα
    • PPARδ
    • PPARγ
  • TGF-β抑制剂

第十章：肝纤维化治疗市场：依给药途径划分

  • 注射药物
    • 静脉
    • 皮下
  • 口服

第十一章：肝纤维化治疗市场：依通路划分

  • 医院药房
  • 网路药房
  • 零售药房
    • 连锁药局
    • 独立经营药房

第十二章：肝纤维化治疗市场：依地区划分

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十三章：肝纤维化治疗市场：依组别划分

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十四章：肝纤维化治疗市场：依国家划分

  • 我们
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十五章：美国肝纤维化治疗药物市场

第十六章：中国肝纤维化治疗药物市场

第十七章 竞争格局

  • 市场集中度分析，2025年
    • 浓度比（CR）
    • 赫芬达尔-赫希曼指数 (HHI)
  • 近期趋势及影响分析，2025 年
  • 2025年产品系列分析
  • 基准分析，2025 年
  • Akero Therapeutics, Inc.
  • AstraZeneca plc
  • BioLineRx Ltd.
  • Boehringer Ingelheim International GmbH
  • Bristol-Myers Squibb Company
  • FibroGen, Inc.
  • Galectin Therapeutics, Inc.
  • Galmed Pharmaceuticals Ltd.
  • Gilead Sciences, Inc.
  • Hepion Pharmaceuticals, Inc.
  • Intercept Pharmaceuticals, Inc.
  • Inventiva SA
  • Ionis Pharmaceuticals, Inc.
  • Johnson & Johnson Services, Inc.
  • Madrigal Pharmaceuticals, Inc.
  • Merck & Co., Inc.
  • Novartis AG
  • Novo Nordisk A/S
  • Pfizer Inc.
  • Zydus Lifesciences Ltd.
Product Code: MRR-437A5D08AE2D

The Liver Fibrosis Drugs Market was valued at USD 17.12 billion in 2025 and is projected to grow to USD 18.83 billion in 2026, with a CAGR of 10.15%, reaching USD 33.70 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 17.12 billion
Estimated Year [2026] USD 18.83 billion
Forecast Year [2032] USD 33.70 billion
CAGR (%) 10.15%

An authoritative introduction to the evolving therapeutic, regulatory, and commercial context shaping liver fibrosis drug development and stakeholder priorities

Liver fibrosis occupies a pivotal intersection of unmet clinical need, scientific innovation, and commercial opportunity. Over the past decade, advances in understanding wound healing, extracellular matrix remodeling, and immunometabolism have reframed fibrotic progression as a tractable therapeutic target rather than an inexorable clinical endpoint. This paradigm shift has catalyzed more diverse therapeutic modalities, encourages cross-disciplinary collaboration between hepatology and immunology experts, and elevates the importance of translational biomarkers that link mechanism to clinical outcomes.

Clinicians, payers, and developers now converge on common priorities: improving diagnostic precision, intervening earlier in the disease course, and demonstrating durable reversal of fibrosis while ensuring safety for chronic administration. Concurrently, regulatory agencies are signaling a willingness to engage on novel endpoints and adaptive trial designs, contingent on rigorously validated surrogate measures. These dynamics create a complex environment where scientific promise must be balanced against operational realities such as supply chain resilience and reimbursement pathways.

Throughout this report, emphasis is placed on how emerging therapies, platform technologies, and stakeholder incentives interact to shape development strategies. The intent is to provide a clear, actionable synthesis that supports decision-makers who must navigate scientific complexity, regulatory nuance, and commercial imperatives simultaneously.

How scientific breakthroughs, modality expansion, and innovative trial designs are driving a fundamental transformation in liver fibrosis therapeutic strategies and stakeholder behavior

The liver fibrosis landscape is undergoing transformative shifts driven by scientific breakthroughs, modality diversification, and changes in clinical trial architecture. Molecular deconvolution of fibrogenic signaling networks has enabled more precise target identification, while advances in biologics, cell and gene therapies, and small molecule design have expanded the therapeutic toolkit. As modalities diversify, developers are increasingly matching mechanism to disease phenotype, prioritizing agents that modulate core drivers of fibrogenesis rather than broadly suppressing associated inflammation.

Clinical development is also being reshaped by innovations in trial design and patient identification. Noninvasive diagnostics and digital biomarkers are enabling earlier enrollment and more efficient assessment of biological effect. These tools facilitate shorter, more informative proof-of-concept studies that reduce risk and accelerate go/no-go decisions. At the same time, partnerships across industry, academia, and contract research organizations are growing in importance as teams combine complementary expertise and capabilities to address complex translational challenges.

Commercially, pricing and access strategies are evolving in tandem with therapeutic differentiation. Payers are focusing on value demonstration through real-world evidence and durable clinical benefit, which is prompting sponsors to incorporate health economics and outcomes research earlier in development. Taken together, these shifts indicate a maturing field where scientific innovation is increasingly paired with pragmatic, outcome-focused development pathways.

Assessing how recent United States tariff shifts have reshaped supply chain resilience, sourcing strategies, and commercial planning across liver fibrosis drug development

Recent tariff policy developments in the United States have introduced a layer of complexity to the global supply chains that underpin drug development and commercialization. Tariff adjustments affect both the procurement of active pharmaceutical ingredients and the sourcing of specialized biologics manufacturing inputs. Manufacturers that rely on cross-border component sourcing have needed to reassess supplier contracts, inventory strategies, and cost structures in order to preserve supply continuity and protect margins.

In response, many organizations have diversified their supplier base, reshored critical manufacturing steps, or expanded inventories of key raw materials to mitigate disruption. These operational shifts have also influenced outsourcing decisions and relationships with contract development and manufacturing organizations, prompting tighter collaboration and increased transparency around lead times and capacity constraints. Regulatory teams, in parallel, are managing the implications for product labeling, import documentation, and quality oversight when manufacturing footprints change.

Strategic pricing and reimbursement discussions have been affected as well, with commercial teams recalibrating launch strategies to account for potential increases in landed costs. Meanwhile, stakeholders across the value chain are placing higher priority on supply chain resilience, dual sourcing, and scenario planning. Collectively, these changes underscore the importance of integrating regulatory, operations, and commercial planning to maintain clinical momentum and ensure patient access amid evolving trade policies.

Multidimensional segmentation insights that connect drug class, mechanism of action, administration route, and distribution channels to inform development and commercialization strategy

Understanding segmentation is essential to aligning research and commercial strategies with therapeutic opportunity. When therapies are organized by drug class, the field spans biologic therapies, cell therapies, gene therapies, and small molecule inhibitors. Within the biologic category, attention centers on monoclonal antibodies and recombinant proteins as platforms that offer target specificity and modulated immune engagement, while small molecule inhibitors encompass both natural product-derived scaffolds and synthetically optimized compounds that enable oral dosing and intracellular target access.

Mechanism-based segmentation further refines prioritization by highlighting ASK1 inhibitors, galectin-3 inhibitors, PPAR agonists, and TGF beta blockers as distinct mechanistic approaches. The PPAR axis itself is subdivided into PPAR alpha, PPAR delta, and PPAR gamma, each presenting differentiated metabolic and fibrotic biology that can be matched to patient phenotypes and comorbidity profiles. Route of administration matters for adherence and chronic treatment planning; injectable therapies, administered either intravenously or subcutaneously, tend to support controlled pharmacokinetics and clinic-based dosing models, whereas oral formulations facilitate outpatient management and broader uptake.

Distribution channels influence commercial execution and patient access. Hospital pharmacies serve acute and inpatient settings where complex biologics and infusion therapies are delivered, online pharmacies enable convenience and continuity for stable chronic regimens, and retail pharmacies-comprising chain and independent outlets-drive outpatient dispensing and direct-to-patient accessibility. Together, these intersecting segmentation lenses offer a multidimensional framework to prioritize development, design clinical programs, and craft go-to-market strategies that reflect modality, mechanism, administration route, and distribution realities.

Regional development and access dynamics that shape regulatory engagement, evidence generation, and commercial execution across multiple global healthcare ecosystems

Regional dynamics exert a profound influence on development priorities, regulatory engagement, and commercial access pathways. In the Americas, regulatory agencies and payers emphasize real-world effectiveness and value-based contracting, which incentivizes sponsors to design evidence generation strategies that demonstrate durable clinical outcomes and cost-of-care impacts. Clinical networks and academic centers across the region also contribute to patient recruitment and biomarker validation efforts, shaping early-phase study design and translational research collaborations.

Across Europe, Middle East & Africa, regulatory harmonization efforts and varying healthcare delivery models require tailored approaches to clinical trial execution and market access planning. European regulatory pathways often prioritize comparability and demonstration of incremental benefit, while regional variations in health technology assessment processes mean that evidence packages must be calibrated to local payer expectations. In parts of the Middle East and Africa, constrained infrastructure and differing prevalence patterns influence the design of implementation studies and access programs.

The Asia-Pacific region presents diverse clinical and commercial environments, with strong capabilities in biologics manufacturing, growing clinical trial capacity, and rapid adoption of digital health tools. Country-specific regulations and reimbursement pathways necessitate early engagement with local stakeholders. Taken together, these regional contours underscore the need for adaptive regulatory strategies, culturally informed patient engagement, and evidence plans that align with payer and provider priorities across geographies.

How company strategies, partnerships, and platform capabilities are converging to drive differentiated pipelines and collaborative approaches in liver fibrosis therapeutics

Company strategies in liver fibrosis are characterized by a mix of platform-driven innovation, targeted product development, and strategic collaboration. Biotech firms are advancing differentiated mechanisms and first-in-class assets, leveraging nimble translational pipelines and focused patient-identification strategies. Larger pharmaceutical companies contribute scale, regulatory experience, and commercialization infrastructure, and increasingly seek partnerships with innovators to accelerate late-stage development and broaden therapeutic portfolios.

Contract research organizations and contract development and manufacturing organizations play a critical role in accelerating timelines and enabling flexible capacity for both biologics and small molecule programs. These partners support adaptive trial designs, complex supply chain coordination, and regulatory submissions across multiple jurisdictions. Strategic alliances, licensing agreements, and co-development deals are common as organizations combine strengths: scientific ingenuity from smaller developers paired with commercial and regulatory capabilities from established firms.

Across the competitive landscape, differentiation arises from clinical efficacy signals, safety profiles amenable to chronic administration, and the ability to demonstrate mechanistic engagement through validated biomarkers. Companies that integrate translational science, patient-centric trial designs, and robust commercial planning are positioned to navigate reimbursement complexities and stakeholder expectations more effectively. The emphasis on collaboration, rather than purely head-to-head competition, reflects the complexity of addressing fibrotic disease biology and the value of complementary capabilities.

Actionable strategic initiatives that align translational biomarkers, supply chain resilience, regional regulatory engagement, and partnership models to accelerate successful therapeutic launches

Industry leaders should prioritize a set of actionable initiatives that align scientific promise with operational and commercial realities. First, integrate translational biomarker strategies early to de-risk clinical programs and create clear links between mechanism of action and clinical endpoints. This alignment will facilitate regulatory dialogue and strengthen value propositions for payers. Second, invest in supply chain resilience by diversifying suppliers for critical inputs, evaluating regional manufacturing options, and establishing contingency plans that preserve clinical and commercial continuity.

Third, pursue strategic collaborations that combine complementary capabilities: emerging innovators should seek partners for late-stage development and commercialization, while established companies can accelerate innovation through targeted licensing and co-development agreements. Fourth, tailor regional strategies to local regulatory and payer landscapes, engaging health technology assessment bodies and regional clinical networks to ensure evidence packages meet local requirements. Finally, design commercial models that reflect route of administration and distribution dynamics: ensure appropriate clinic-based support for injectable therapies and frictionless retail and online fulfillment for oral regimens.

By executing these recommendations, organizations can translate scientific advances into durable clinical impact while managing operational complexity and aligning stakeholder incentives across development and commercialization pathways.

A rigorous mixed-methods research approach combining expert primary interviews, systematic secondary literature review, and operational analysis to validate therapeutic and commercial insights

The research behind this report combines multiple methodological approaches to ensure a robust and evidence-based perspective. Primary research included structured interviews with clinical experts in hepatology, regulatory advisors, industry executives, and supply chain specialists to capture current practice patterns, regulatory expectations, and operational constraints. These qualitative insights were synthesized to contextualize therapeutic differentiation and to illuminate decision points that influence development and commercialization strategies.

Secondary research encompassed a systematic review of peer-reviewed literature, clinical trial registries, and publicly available regulatory guidance to map mechanistic rationales, clinical endpoints, and translational biomarkers. Operational analysis leveraged industry reports on manufacturing capabilities, supply chain frameworks, and distribution models to assess practical implications for development and market entry. Throughout the process, triangulation of evidence was applied to validate conclusions and to ensure that interpretations reflected multiple perspectives.

Analytical rigor was maintained through iterative validation with subject matter experts and cross-functional reviewers. The methodology prioritized clarity and reproducibility, with an emphasis on linking mechanistic science to clinical trial design and commercial execution. This approach supports decision-makers seeking actionable intelligence grounded in both scientific evidence and operational feasibility.

A conclusive synthesis highlighting actionable priorities across science, clinical development, operations, and commercial execution to realize durable therapeutic impact in liver fibrosis

In summary, the liver fibrosis therapeutic landscape is transitioning from conceptual promise to pragmatic execution. Scientific advances in target biology and modality engineering have expanded the set of viable interventions, while innovations in diagnostics and trial design are enabling more efficient proof-of-concept work. At the same time, operational pressures-ranging from supply chain shifts to tariff-related sourcing considerations-require integrated planning across R&D, manufacturing, and commercial teams.

Success in this environment will hinge on the ability to align mechanistic clarity with translational biomarkers, to design patient-centric clinical programs that reflect route of administration and distribution realities, and to engage payers and regulators early with robust evidence strategies. Strategic collaborations and adaptive operational models will be key enablers, allowing organizations to combine scientific differentiation with scale and market access expertise.

The outcome-oriented approach advocated throughout this report emphasizes measurable clinical benefit, durable patient outcomes, and pragmatic pathways to access. Stakeholders that adopt data-driven development, prioritize supply chain resilience, and pursue partnerships that complement internal capabilities will be best positioned to convert scientific innovation into sustained clinical and commercial success.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Liver Fibrosis Drugs Market, by Drug Class

  • 8.1. Biologic Therapies
    • 8.1.1. Monoclonal Antibodies
    • 8.1.2. Recombinant Proteins
  • 8.2. Cell Therapies
  • 8.3. Gene Therapies
  • 8.4. Small Molecule Inhibitors
    • 8.4.1. Natural Products
    • 8.4.2. Synthetic Compounds

9. Liver Fibrosis Drugs Market, by Mechanism Of Action

  • 9.1. ASK1 Inhibitors
  • 9.2. Galectin-3 Inhibitors
  • 9.3. PPAR Agonists
    • 9.3.1. PPAR Alpha
    • 9.3.2. PPAR Delta
    • 9.3.3. PPAR Gamma
  • 9.4. TGF Beta Blockers

10. Liver Fibrosis Drugs Market, by Route Of Administration

  • 10.1. Injectable
    • 10.1.1. Intravenous
    • 10.1.2. Subcutaneous
  • 10.2. Oral

11. Liver Fibrosis Drugs Market, by Distribution Channel

  • 11.1. Hospital Pharmacy
  • 11.2. Online Pharmacy
  • 11.3. Retail Pharmacy
    • 11.3.1. Chain Pharmacy
    • 11.3.2. Independent Pharmacy

12. Liver Fibrosis Drugs Market, by Region

  • 12.1. Americas
    • 12.1.1. North America
    • 12.1.2. Latin America
  • 12.2. Europe, Middle East & Africa
    • 12.2.1. Europe
    • 12.2.2. Middle East
    • 12.2.3. Africa
  • 12.3. Asia-Pacific

13. Liver Fibrosis Drugs Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Liver Fibrosis Drugs Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. United States Liver Fibrosis Drugs Market

16. China Liver Fibrosis Drugs Market

17. Competitive Landscape

  • 17.1. Market Concentration Analysis, 2025
    • 17.1.1. Concentration Ratio (CR)
    • 17.1.2. Herfindahl Hirschman Index (HHI)
  • 17.2. Recent Developments & Impact Analysis, 2025
  • 17.3. Product Portfolio Analysis, 2025
  • 17.4. Benchmarking Analysis, 2025
  • 17.5. Akero Therapeutics, Inc.
  • 17.6. AstraZeneca plc
  • 17.7. BioLineRx Ltd.
  • 17.8. Boehringer Ingelheim International GmbH
  • 17.9. Bristol-Myers Squibb Company
  • 17.10. FibroGen, Inc.
  • 17.11. Galectin Therapeutics, Inc.
  • 17.12. Galmed Pharmaceuticals Ltd.
  • 17.13. Gilead Sciences, Inc.
  • 17.14. Hepion Pharmaceuticals, Inc.
  • 17.15. Intercept Pharmaceuticals, Inc.
  • 17.16. Inventiva S.A.
  • 17.17. Ionis Pharmaceuticals, Inc.
  • 17.18. Johnson & Johnson Services, Inc.
  • 17.19. Madrigal Pharmaceuticals, Inc.
  • 17.20. Merck & Co., Inc.
  • 17.21. Novartis AG
  • 17.22. Novo Nordisk A/S
  • 17.23. Pfizer Inc.
  • 17.24. Zydus Lifesciences Ltd.

LIST OF FIGURES

  • FIGURE 1. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL LIVER FIBROSIS DRUGS MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL LIVER FIBROSIS DRUGS MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. UNITED STATES LIVER FIBROSIS DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 12. CHINA LIVER FIBROSIS DRUGS MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY BIOLOGIC THERAPIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY BIOLOGIC THERAPIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY BIOLOGIC THERAPIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY BIOLOGIC THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY RECOMBINANT PROTEINS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY RECOMBINANT PROTEINS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY RECOMBINANT PROTEINS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY CELL THERAPIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY CELL THERAPIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY CELL THERAPIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY GENE THERAPIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY GENE THERAPIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY GENE THERAPIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY SMALL MOLECULE INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY SMALL MOLECULE INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY SMALL MOLECULE INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY SMALL MOLECULE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY NATURAL PRODUCTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY NATURAL PRODUCTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY NATURAL PRODUCTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY SYNTHETIC COMPOUNDS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY SYNTHETIC COMPOUNDS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY SYNTHETIC COMPOUNDS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY ASK1 INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY ASK1 INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY ASK1 INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY GALECTIN-3 INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY GALECTIN-3 INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY GALECTIN-3 INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY PPAR AGONISTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY PPAR AGONISTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY PPAR AGONISTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY PPAR AGONISTS, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY PPAR ALPHA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY PPAR ALPHA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY PPAR ALPHA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY PPAR DELTA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY PPAR DELTA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY PPAR DELTA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY PPAR GAMMA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY PPAR GAMMA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY PPAR GAMMA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY TGF BETA BLOCKERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY TGF BETA BLOCKERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY TGF BETA BLOCKERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY INJECTABLE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY INJECTABLE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY INJECTABLE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY INTRAVENOUS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY INTRAVENOUS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY SUBCUTANEOUS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY SUBCUTANEOUS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY ORAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY ORAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY HOSPITAL PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY HOSPITAL PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY ONLINE PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY ONLINE PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY RETAIL PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY RETAIL PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY RETAIL PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY CHAIN PHARMACY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY CHAIN PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY CHAIN PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY INDEPENDENT PHARMACY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY INDEPENDENT PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY INDEPENDENT PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 84. AMERICAS LIVER FIBROSIS DRUGS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 85. AMERICAS LIVER FIBROSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 86. AMERICAS LIVER FIBROSIS DRUGS MARKET SIZE, BY BIOLOGIC THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 87. AMERICAS LIVER FIBROSIS DRUGS MARKET SIZE, BY SMALL MOLECULE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 88. AMERICAS LIVER FIBROSIS DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 89. AMERICAS LIVER FIBROSIS DRUGS MARKET SIZE, BY PPAR AGONISTS, 2018-2032 (USD MILLION)
  • TABLE 90. AMERICAS LIVER FIBROSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 91. AMERICAS LIVER FIBROSIS DRUGS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 92. AMERICAS LIVER FIBROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 93. AMERICAS LIVER FIBROSIS DRUGS MARKET SIZE, BY RETAIL PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 94. NORTH AMERICA LIVER FIBROSIS DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 95. NORTH AMERICA LIVER FIBROSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 96. NORTH AMERICA LIVER FIBROSIS DRUGS MARKET SIZE, BY BIOLOGIC THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 97. NORTH AMERICA LIVER FIBROSIS DRUGS MARKET SIZE, BY SMALL MOLECULE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 98. NORTH AMERICA LIVER FIBROSIS DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 99. NORTH AMERICA LIVER FIBROSIS DRUGS MARKET SIZE, BY PPAR AGONISTS, 2018-2032 (USD MILLION)
  • TABLE 100. NORTH AMERICA LIVER FIBROSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 101. NORTH AMERICA LIVER FIBROSIS DRUGS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 102. NORTH AMERICA LIVER FIBROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 103. NORTH AMERICA LIVER FIBROSIS DRUGS MARKET SIZE, BY RETAIL PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 104. LATIN AMERICA LIVER FIBROSIS DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 105. LATIN AMERICA LIVER FIBROSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 106. LATIN AMERICA LIVER FIBROSIS DRUGS MARKET SIZE, BY BIOLOGIC THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 107. LATIN AMERICA LIVER FIBROSIS DRUGS MARKET SIZE, BY SMALL MOLECULE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 108. LATIN AMERICA LIVER FIBROSIS DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 109. LATIN AMERICA LIVER FIBROSIS DRUGS MARKET SIZE, BY PPAR AGONISTS, 2018-2032 (USD MILLION)
  • TABLE 110. LATIN AMERICA LIVER FIBROSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 111. LATIN AMERICA LIVER FIBROSIS DRUGS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 112. LATIN AMERICA LIVER FIBROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 113. LATIN AMERICA LIVER FIBROSIS DRUGS MARKET SIZE, BY RETAIL PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 114. EUROPE, MIDDLE EAST & AFRICA LIVER FIBROSIS DRUGS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 115. EUROPE, MIDDLE EAST & AFRICA LIVER FIBROSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 116. EUROPE, MIDDLE EAST & AFRICA LIVER FIBROSIS DRUGS MARKET SIZE, BY BIOLOGIC THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 117. EUROPE, MIDDLE EAST & AFRICA LIVER FIBROSIS DRUGS MARKET SIZE, BY SMALL MOLECULE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 118. EUROPE, MIDDLE EAST & AFRICA LIVER FIBROSIS DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 119. EUROPE, MIDDLE EAST & AFRICA LIVER FIBROSIS DRUGS MARKET SIZE, BY PPAR AGONISTS, 2018-2032 (USD MILLION)
  • TABLE 120. EUROPE, MIDDLE EAST & AFRICA LIVER FIBROSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 121. EUROPE, MIDDLE EAST & AFRICA LIVER FIBROSIS DRUGS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 122. EUROPE, MIDDLE EAST & AFRICA LIVER FIBROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 123. EUROPE, MIDDLE EAST & AFRICA LIVER FIBROSIS DRUGS MARKET SIZE, BY RETAIL PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 124. EUROPE LIVER FIBROSIS DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 125. EUROPE LIVER FIBROSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 126. EUROPE LIVER FIBROSIS DRUGS MARKET SIZE, BY BIOLOGIC THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 127. EUROPE LIVER FIBROSIS DRUGS MARKET SIZE, BY SMALL MOLECULE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 128. EUROPE LIVER FIBROSIS DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 129. EUROPE LIVER FIBROSIS DRUGS MARKET SIZE, BY PPAR AGONISTS, 2018-2032 (USD MILLION)
  • TABLE 130. EUROPE LIVER FIBROSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 131. EUROPE LIVER FIBROSIS DRUGS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 132. EUROPE LIVER FIBROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 133. EUROPE LIVER FIBROSIS DRUGS MARKET SIZE, BY RETAIL PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 134. MIDDLE EAST LIVER FIBROSIS DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 135. MIDDLE EAST LIVER FIBROSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 136. MIDDLE EAST LIVER FIBROSIS DRUGS MARKET SIZE, BY BIOLOGIC THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 137. MIDDLE EAST LIVER FIBROSIS DRUGS MARKET SIZE, BY SMALL MOLECULE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 138. MIDDLE EAST LIVER FIBROSIS DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 139. MIDDLE EAST LIVER FIBROSIS DRUGS MARKET SIZE, BY PPAR AGONISTS, 2018-2032 (USD MILLION)
  • TABLE 140. MIDDLE EAST LIVER FIBROSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 141. MIDDLE EAST LIVER FIBROSIS DRUGS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 142. MIDDLE EAST LIVER FIBROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 143. MIDDLE EAST LIVER FIBROSIS DRUGS MARKET SIZE, BY RETAIL PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 144. AFRICA LIVER FIBROSIS DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 145. AFRICA LIVER FIBROSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 146. AFRICA LIVER FIBROSIS DRUGS MARKET SIZE, BY BIOLOGIC THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 147. AFRICA LIVER FIBROSIS DRUGS MARKET SIZE, BY SMALL MOLECULE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 148. AFRICA LIVER FIBROSIS DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 149. AFRICA LIVER FIBROSIS DRUGS MARKET SIZE, BY PPAR AGONISTS, 2018-2032 (USD MILLION)
  • TABLE 150. AFRICA LIVER FIBROSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 151. AFRICA LIVER FIBROSIS DRUGS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 152. AFRICA LIVER FIBROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 153. AFRICA LIVER FIBROSIS DRUGS MARKET SIZE, BY RETAIL PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 154. ASIA-PACIFIC LIVER FIBROSIS DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 155. ASIA-PACIFIC LIVER FIBROSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 156. ASIA-PACIFIC LIVER FIBROSIS DRUGS MARKET SIZE, BY BIOLOGIC THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 157. ASIA-PACIFIC LIVER FIBROSIS DRUGS MARKET SIZE, BY SMALL MOLECULE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 158. ASIA-PACIFIC LIVER FIBROSIS DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 159. ASIA-PACIFIC LIVER FIBROSIS DRUGS MARKET SIZE, BY PPAR AGONISTS, 2018-2032 (USD MILLION)
  • TABLE 160. ASIA-PACIFIC LIVER FIBROSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 161. ASIA-PACIFIC LIVER FIBROSIS DRUGS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 162. ASIA-PACIFIC LIVER FIBROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 163. ASIA-PACIFIC LIVER FIBROSIS DRUGS MARKET SIZE, BY RETAIL PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 164. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 165. ASEAN LIVER FIBROSIS DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 166. ASEAN LIVER FIBROSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 167. ASEAN LIVER FIBROSIS DRUGS MARKET SIZE, BY BIOLOGIC THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 168. ASEAN LIVER FIBROSIS DRUGS MARKET SIZE, BY SMALL MOLECULE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 169. ASEAN LIVER FIBROSIS DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 170. ASEAN LIVER FIBROSIS DRUGS MARKET SIZE, BY PPAR AGONISTS, 2018-2032 (USD MILLION)
  • TABLE 171. ASEAN LIVER FIBROSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 172. ASEAN LIVER FIBROSIS DRUGS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 173. ASEAN LIVER FIBROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 174. ASEAN LIVER FIBROSIS DRUGS MARKET SIZE, BY RETAIL PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 175. GCC LIVER FIBROSIS DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 176. GCC LIVER FIBROSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 177. GCC LIVER FIBROSIS DRUGS MARKET SIZE, BY BIOLOGIC THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 178. GCC LIVER FIBROSIS DRUGS MARKET SIZE, BY SMALL MOLECULE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 179. GCC LIVER FIBROSIS DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 180. GCC LIVER FIBROSIS DRUGS MARKET SIZE, BY PPAR AGONISTS, 2018-2032 (USD MILLION)
  • TABLE 181. GCC LIVER FIBROSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 182. GCC LIVER FIBROSIS DRUGS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 183. GCC LIVER FIBROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 184. GCC LIVER FIBROSIS DRUGS MARKET SIZE, BY RETAIL PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 185. EUROPEAN UNION LIVER FIBROSIS DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 186. EUROPEAN UNION LIVER FIBROSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 187. EUROPEAN UNION LIVER FIBROSIS DRUGS MARKET SIZE, BY BIOLOGIC THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 188. EUROPEAN UNION LIVER FIBROSIS DRUGS MARKET SIZE, BY SMALL MOLECULE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 189. EUROPEAN UNION LIVER FIBROSIS DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 190. EUROPEAN UNION LIVER FIBROSIS DRUGS MARKET SIZE, BY PPAR AGONISTS, 2018-2032 (USD MILLION)
  • TABLE 191. EUROPEAN UNION LIVER FIBROSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 192. EUROPEAN UNION LIVER FIBROSIS DRUGS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 193. EUROPEAN UNION LIVER FIBROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 194. EUROPEAN UNION LIVER FIBROSIS DRUGS MARKET SIZE, BY RETAIL PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 195. BRICS LIVER FIBROSIS DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 196. BRICS LIVER FIBROSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 197. BRICS LIVER FIBROSIS DRUGS MARKET SIZE, BY BIOLOGIC THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 198. BRICS LIVER FIBROSIS DRUGS MARKET SIZE, BY SMALL MOLECULE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 199. BRICS LIVER FIBROSIS DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 200. BRICS LIVER FIBROSIS DRUGS MARKET SIZE, BY PPAR AGONISTS, 2018-2032 (USD MILLION)
  • TABLE 201. BRICS LIVER FIBROSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 202. BRICS LIVER FIBROSIS DRUGS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 203. BRICS LIVER FIBROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 204. BRICS LIVER FIBROSIS DRUGS MARKET SIZE, BY RETAIL PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 205. G7 LIVER FIBROSIS DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 206. G7 LIVER FIBROSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 207. G7 LIVER FIBROSIS DRUGS MARKET SIZE, BY BIOLOGIC THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 208. G7 LIVER FIBROSIS DRUGS MARKET SIZE, BY SMALL MOLECULE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 209. G7 LIVER FIBROSIS DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 210. G7 LIVER FIBROSIS DRUGS MARKET SIZE, BY PPAR AGONISTS, 2018-2032 (USD MILLION)
  • TABLE 211. G7 LIVER FIBROSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 212. G7 LIVER FIBROSIS DRUGS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 213. G7 LIVER FIBROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 214. G7 LIVER FIBROSIS DRUGS MARKET SIZE, BY RETAIL PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 215. NATO LIVER FIBROSIS DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 216. NATO LIVER FIBROSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 217. NATO LIVER FIBROSIS DRUGS MARKET SIZE, BY BIOLOGIC THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 218. NATO LIVER FIBROSIS DRUGS MARKET SIZE, BY SMALL MOLECULE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 219. NATO LIVER FIBROSIS DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 220. NATO LIVER FIBROSIS DRUGS MARKET SIZE, BY PPAR AGONISTS, 2018-2032 (USD MILLION)
  • TABLE 221. NATO LIVER FIBROSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 222. NATO LIVER FIBROSIS DRUGS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 223. NATO LIVER FIBROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 224. NATO LIVER FIBROSIS DRUGS MARKET SIZE, BY RETAIL PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 225. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 226. UNITED STATES LIVER FIBROSIS DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 227. UNITED STATES LIVER FIBROSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 228. UNITED STATES LIVER FIBROSIS DRUGS MARKET SIZE, BY BIOLOGIC THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 229. UNITED STATES LIVER FIBROSIS DRUGS MARKET SIZE, BY SMALL MOLECULE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 230. UNITED STATES LIVER FIBROSIS DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 231. UNITED STATES LIVER FIBROSIS DRUGS MARKET SIZE, BY PPAR AGONISTS, 2018-2032 (USD MILLION)
  • TABLE 232. UNITED STATES LIVER FIBROSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 233. UNITED STATES LIVER FIBROSIS DRUGS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 234. UNITED STATES LIVER FIBROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 235. UNITED STATES LIVER FIBROSIS DRUGS MARKET SIZE, BY RETAIL PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 236. CHINA LIVER FIBROSIS DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 237. CHINA LIVER FIBROSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 238. CHINA LIVER FIBROSIS DRUGS MARKET SIZE, BY BIOLOGIC THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 239. CHINA LIVER FIBROSIS DRUGS MARKET SIZE, BY SMALL MOLECULE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 240. CHINA LIVER FIBROSIS DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 241. CHINA LIVER FIBROSIS DRUGS MARKET SIZE, BY PPAR AGONISTS, 2018-2032 (USD MILLION)
  • TABLE 242. CHINA LIVER FIBROSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 243. CHINA LIVER FIBROSIS DRUGS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 244. CHINA LIVER FIBROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 245. CHINA LIVER FIBROSIS DRUGS MARKET SIZE, BY RETAIL PHARMACY, 2018-2032 (USD MILLION)